Lilly vs Pfizer: Obesity Race Reaches Market Highs
Lilly leads the GLP-1 obesity wave as Pfizer rebuilds with deals and repurposed assets. Q1 2026 results underscore tw...
This piece explains glide path withdrawal strategies for index funds, focusing on steady income while managing sequence of returns risk.
25,847 articlesLilly leads the GLP-1 obesity wave as Pfizer rebuilds with deals and repurposed assets. Q1 2026 results underscore tw...
Investors are weighing a 32% drop in Netflix stock since April after Reed Hastings signaled a board exit. Here’s how ...
Oil around $75 invites questions about ConocoPhillips stock. This guide breaks down how to assess COP, weigh oil sens...
Daily RSI divergence is signaling momentum fatigue for ETH, even as prices hover near key supports. This ethereum pri...
The market buzz around Sweetgreen stock is loud, but hype isn’t a plan. This article weighs momentum against business...
Two benchmarks gave two opposite results for Claude Fable 5. The mystery isn't a nerf—it's the routing layer. Learn h...
Tesla is signaling a profitability-focused future with autonomy and robotics, while BYD drives volume with affordable...
Palantir rallies on stronger AI demand and improving margins, positioning it as a core pick in this best stocks 2026 ...
A new Morgan Stanley note argues Rocket Lab’s shift into satellite data and services could unlock substantial upside,...
Goldman Sachs warns that China's oil demand may not return to its pre-crisis trajectory, highlighting a potential, la...
As July 29 approaches, investors ask if they should microsoft stock before the earnings release. This guide breaks do...
Value investing meets AI: compare Microsoft and NVIDIA to see which better value stock fits a careful, long-term appr...